Maximizing opportunities for its proprietary ARCUS genome editing platform was among the priorities Precision BioSciences articulated last fall when it named veteran biotech executive Michael Amoroso ...
Interim results from investigator-assessed responses in first 40 patients from TSC1 and TSC2 arms demonstrate sustained tumor reductions in heavily pre-treated population 80 patients now enrolled in ...
LOS ANGELES, Dec. 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results